Selected Publications
Slater RL, Lai Y, Zhong Y, Li H, Meng Y, Homet Moreno B, Godwin JL, Frenkl T, Sonpavde GP, Mamtani R.: The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. J Med Econ : 2020.
Bange EM, Doucette A, Gabriel PE, Porterfield F, Harrigan JJ, Wang R, Wojcieszynski AP, Boursi B, Mooney BI, Reiss KA, Mamtani R.: Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. JCO Oncol Pract : 2020.
Takvorian SU, Oganisian A, Mamtani R, Mitra N, Shulman LN, Bekelman JE, Werner RM.: Association of Medicaid Expansion Under the Affordable Care Act With Insurance Status, Cancer Stage, and Timely Treatment Among Patients With Breast, Colon, and Lung Cancer JAMA Netw Open : 2020.
Parikh RB, Feld EK, Galsky MD, Adamson BJ, Cohen AB, Baxi SS, Boursi SB, Christodouleas JP, Vaughn DJ, Meropol NJ, Mamtani R.: First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis. Future Oncol : 2020.
Ben Boursi, Jared S Huber, Kevin Haynes, Ronac Mamtani, Yu-Xiao Yang: Digoxin use is associated with pancreatic cancer risk but does not affect survival Cancer Causes Control
: 2020.
Hale O, Patterson K, Lai Y, Meng Y, Li H, Godwin JL, Homet Moreno B, Mamtani R.: Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States. Clin Genitourin Cancer : 2020.
Margalit O, Shacham-Shmueli E, Yang YX, Lawerence YR, Levy I, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Mamtani R, Boursi B.: Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma Oncologist : 2020.
Ravi B Parikh, Kyle W Robinson, Sumedha Chhatre, Elina Medvedeva, John P Cashy, Shika Veera, Joshua M Bauml, Tito Fojo, Amol S Navathe, S Bruce Malkowicz, Ronac Mamtani, Ravishankar Jayadevappa: Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018 JAMA Netw Open : 2020.
Parikh RB, Feld EK, Galsky MD, Adamson BJ, Cohen AB, Baxi SS, Boursi SB, Christodouleas JP, Vaughn DJ, Meropol NJ, Mamtani R.: First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis Future Oncol. : 2019.
Vajravelu RK, Copelovitch L, Osterman MT, Scott FI, Mamtani R, Lewis JD, Denburg MR.: Risk for Chronic Kidney Disease in Patients with Inflammatory Bowel Diseases Increases with Age but is not Associated with 5-aminosalicylate Use Clin Gastroenterol Hepatol pii: S1542-3565 (19): 31245-5,2019.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia,
PA
19147
Phone: 215-662-7606
Patient appointments: 800-789-7366